Clinical trials: Malignant Colorectal Neoplasm
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Colorectal Cancer, Metastatic Cancer
Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer
RATIONALE: Inserting the interleukin-12 gene into a person's cancer cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00072098
- Testing
- adenovirus vector, interleukin-12 gene
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Max Sung
Colon Cancer Screening
Rural Colon Cancer Screening Toolkit Intervention
Less than half of all positive fecal immunochemical testing (FIT)s are followed-up by colonoscopy, thus limiting the full potential of colorectal cancer (CRC) screening to reduce mortality.
- Trial name
- NCT04651504
- Testing
- Colorectal Cancer Toolkit
- Where
- United States
- Volunteers
- 185,903 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Endometrial Cancer
Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer
Randomized phase II trial to compare two different hormone therapy regimens in preventing endometrial cancer in women who have a genetic risk for hereditary nonpolyposis colon cancer.
- Trial name
- NCT00033358
- Testing
- medroxyprogesterone, ethinyl estradiol, norgestrel
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy
RATIONALE: Monoclonal antibodies such as anti-cytotoxic T-lymphocyte-associated antigen-4 can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00047164
- Testing
- ipilimumab
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Colon Cancer
Prospective, Controlled, Randomized Multicentric Study on the Management of the Vesical Catheter in Colon Surgery.
INTRODUCTION: Recommendations for peroperative bladder catheterization remain a controversial issue since it is a procedure that is not without complications.
- Trial name
- NCT04070898
- Testing
- Remove urinary catheter after surgery
- Where
- Spain
- Volunteers
- 416 people
- Sponsor
- Corporacion Parc Tauli
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative
- Trial name
- DUET-3 (NCT03752398)
- Testing
- XmAb®23104, Yervoy® (ipilimumab)
- Where
- 18 sites in United States
- Volunteers
- 198 people
- Sponsor
- Xencor, Inc.
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
A phase I/II study of PI3Kinase inhibition (copanlisib) and anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in mismatch-repair proficient (MSS) colorectal cancer.
- Trial name
- NCT03711058
- Testing
- Copanlisib, Nivolumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Colon Cancer, Recurrent Rectal Cancer
Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
The study will determine the maximum tolerated dose (MTD) of AUY922 given in combination with cetuximab in previously treated patients with KRAS wild-type metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- NCT01294826
- Testing
- AUY922, Cetuximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Swedish Medical Center
Colorectal Cancer
Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00107315
- Testing
- bevacizumab, capecitabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Colon Neoplasm
Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
This study aims to elucidate the regression effects of neoadjuvant chemotherapy combined with immunotherapy and adjuvant therapy in locally advanced MSS colon cancer.
- Trial name
- ICONIC (NCT05914389)
- Testing
- Oxaliplatin, Capecitabine, Anti-PD-L1 Monoclonal Antibody
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Cancer
Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Cyclosporine may relieve the diarrhea caused by irinotecan.
- Trial name
- NCT00003950
- Testing
- cyclosporine, CPT-11
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of Chicago
Colon Cancer
Evaluation of Interest Chemo-oncogramme in Patients With Colonic Adenocarcinoma Stage 4
In patients with colonic adenocarcinoma stage 4 which are potentially resectable metastases (lung and liver metastases), treatment with chemotherapy is necessary but not end in success in 10% of cases.
- Trial name
- Oncogramme (NCT02305368)
- Testing
- Chimio-oncogramme
- Volunteers
- 20 people
- Sponsor
- University Hospital, Limoges
Colorectal Neoplasms Malignant
The COLON Study: Colorectal Cancer Cohort
The main aim of this observational, prospective cohort study is to assess associations of diet and other lifestyle factors with colorectal cancer recurrence, survival and quality of life.
- Trial name
- COLON (NCT03191110)
- Testing
- No intervention: observational study
- Where
- 11 sites in Netherlands
- Volunteers
- 2,000 people
- Sponsor
- Wageningen University
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
- Trial name
- NCT06607185
- Testing
- LY4066434., Cetuximab, Nab paclitaxel
- Where
- 45 sites in United States, Belgium and 6 more
- Volunteers
- 750 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer
Participatory Research to Advance Colon Cancer Prevention
The overall goal of this study is to test strategies to raise rates of colorectal cancer screening among the Latino population in a federally qualified health center that operates multiple clinics.
- Trial name
- PROMPT (NCT03167125)
- Testing
- Automated Prompts, Automated Plus Live Prompts
- Where
- United States
- Volunteers
- 27,580 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Colon Cancer Stage III
Lymph Node Ratio and Kras Mutation in R Colon Cancer
clinical impact of LN ratio with Kras expression in colon cancer
- Trial name
- NCT04342676
- Testing
- k ras, Panitumumab
- Where
- Egypt
- Volunteers
- 433 people
- Sponsor
- Mansoura University
Liver Metastases, Colon Cancer
Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases
Patients are invited to participate in a research study of liver perfusion (how blood flows to the liver over time). Researchers hope to learn whether perfusion characteristics of liver metastases may be predictive of response to…
- Trial name
- NCT01631318
- Testing
- Dynamic contrast-enhanced ultrasound imaging, Optical Tracking Device, Electromagnetic Tracking Device
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Stanford University
Ascending Colon Cancer, Proximal Transverse Colon Cancer
LIRRH Trial for the Right-sided Colon Cancer
The aim of this clinical trial is to compare the short- and long-term outcomes of laparoscopic ileocecal reconstruction right hemicolectomy (LIRRH) with those of traditional laparoscopic right hemicolectomy (TRH) for ascending…
- Trial name
- LIRRH (NCT07207317)
- Testing
- Laparoscopic ileocecal-reconstruction right hemicolectomy (LIRRH), traditional laparoscopic right hemicolectomy (TRH)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chaoxi Zhou
Recurrent Colon Cancer, Recurrent Rectal Cancer
Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer
This phase II trial is studying dasatinib to see how well it works in treating patients with previously treated metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- NCT00504153
- Testing
- dasatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.